CSafe, a leader in pharmaceutical cold chain shipping solutions, introduces the CGT Ultra D, a multi-use dry ice dewar designed for advanced therapy medicinal products (ATMPs). This product maintains temperatures below -70°C for an industry-leading 37+ days. The CGT Ultra D will debut at the Meeting on the Mesa conference in Phoenix, Arizona, from October 7-9. Attendees can visit CSafe’s booth for a preview of the upcoming single-use CGT Cryo S dewar.
CSafe’s CEO, Patrick Schafer, highlights the company’s commitment to supporting secure cell and gene therapy transport. As ATMPs develop and scale, CSafe aims to assist organizations in their commercialization process with its global footprint and industry expertise.
The launch of CGT Ultra D and CGT Cryo S completes CSafe’s dewar lineup, ensuring top-tier temperature performance. These dewars feature TracSafe RLT data loggers that offer real-time GPS and condition data via CSafe Connect.
Emilio Frattaruolo, Vice President of Cell & Gene Therapies at CSafe, notes the excitement over presenting the CGT Ultra D and previewing the CGT Cryo S. This expansion provides customers with superior thermal performance and data logging.
Earlier this year, the CGT Cryo M, a liquid nitrogen dewar, was launched, maintaining temperatures below -150°C for over 10 days. CSafe also offers a dry ice CGT Ultra parcel shipper with variable payload sizes, all compliant with ISTA 7D testing standards.
